Harpoon Therapeutics has given up on its onetime lead prospect HPN424. A phase 1/2a prostate cancer clinical trial found the PSMA-targeting T-cell engager had “modest activity with a tolerability ...
India’s Defense Minister Rajnath Singh at the National War Memorial to pay homage to the fallen heroes on the occasion of Kargil Vijay Diwas, in New Delhi on July 26. (ANI photo) NEW DELHI/WASHINGTON ...
AbbVie has punctured Harpoon Therapeutics’ dream of a $200 million payday. Needing to pay the sum to take up its option on the anti-BCMA T-cell engager HPN217, AbbVie has opted against moving deeper ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results